Covered recipient · General Payments record
ERIC HARRIS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$2,886.44
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,635.79 | 151 |
| Long term medical supply or device loan | $166.66 | 2 |
| Education | $83.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERIC HARRIS
NPI 1902068158 · CMS profile ID 1072128
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DAYTONA BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- ERIC HARRIS, NPI 1902068158, CMS profile ID 1072128, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–154 of 154 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1902068158?year=2023&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $2,886.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–154 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.74 | 01/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992316699 | CMS |
| Amgen Inc. | $13.93 | 01/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020574931 | CMS |
| Alexion Pharmaceuticals, Inc. | $13.87 | 01/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017084835 | CMS |
| Gilead Sciences, Inc. | $16.52 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025945677 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $410,930.93 | 27 |
| PY2024 | Principal investigator | $136,923.17 | 6 |
| PY2023 | Principal investigator | $155,405.02 | 56 |
| PY2022 | Principal investigator | $101,696.25 | 37 |
| PY2021 | Principal investigator | $120,951.45 | 53 |
| PY2020 | Principal investigator | $138,401.05 | 33 |
| PY2019 | Principal investigator | $10,486.75 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Eli Lilly and Company | $22,700.00 | 12/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187882694 |
| Principal investigator 1 | Genentech, Inc. | $2,025.50 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649116 |
| Principal investigator 1 | Genentech, Inc. | $169.00 | 11/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649109 |
| Principal investigator 1 | Genentech, Inc. | $1,963.00 | 11/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649112 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,749.00 | 11/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235993909 |
| Principal investigator 1 | Eli Lilly and Company | $541.09 | 10/27/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187881180 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,262.50 | 07/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185545743 |
| Principal investigator 1 | Genentech, Inc. | $728.00 | 07/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649090 |
| Principal investigator 1 | Genentech, Inc. | $142.00 | 07/11/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649101 |
| Principal investigator 1 | Genentech, Inc. | $12,751.00 | 07/10/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649106 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,767.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 1185545735 |
| Principal investigator 1 | Genentech, Inc. | $2,345.00 | 07/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649097 |
| Principal investigator 1 | Genentech, Inc. | $146.00 | 07/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211649095 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $824.70 | 06/24/2025 | Non-covered Recipient Entity Florida Cancer Specialists | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235997359 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,800.00 | 06/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185545733 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $35,965.76 | 05/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185545737 |
| Principal investigator 1 | BeiGene, Ltd. | $84.20 | 05/19/2025 | Non-covered Recipient Entity Florida Cancer Specialist (SCRI) - Fort Myers | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190325072 |
| Principal investigator 1 | Celgene Corporation | $7,083.00 | 05/14/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute Llc | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1222306687 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,000.00 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 1185545731 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $99,562.89 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185545739 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,250.00 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185545741 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,280.00 | 04/14/2025 | Non-covered Recipient Entity FCS Research East | A Phase 2, Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation | No dispute reported | 06/30/2026 | 1232936220 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $9,534.00 | 04/04/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy | No dispute reported | 06/30/2026 | 1236530664 |
| Principal investigator 1 | Celgene Corporation | $54,776.33 | 02/05/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma | No dispute reported | 06/30/2026 | 1222305652 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,122.84 | 01/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185545747 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,400.00 | 01/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 1185545745 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $22,958.12 | 01/06/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | No dispute reported | 06/30/2026 | 1236530659 |